title: Inhibitory effect of PPAR-gamma activator on IL-6 and mPGES protein expression in PBMC induced by homocysteine.
abstract: The objective was to investigate the relationship between homocysteine (HCY), peroxisome proliferator-activated receptors (PPAR)-gamma and the expression of interleukin 6 (IL-6) and microsomal prostaglandin E synthase (mPGES) by peripheral blood mononuclear cell (PBMC) culture in vitro, as well as to look at the intervention with HCY and PPAR-gamma activators (troglitazone and rosiglitazone). PBMC were isolated from venous blood of normal volunteers and incubated with HCY and PPAR-gamma activator of varying concentrations for 24 hr. The supernatant of the culture medium was collected in order to determine the IL-6 and mPGES levels by ELISA assay. The results show that the expression of IL-6 and mPGES in the HCY experimental group was significantly higher than that in the control group (p<0.01 and p<0.05, respectively). Additionally, the IL-6 and mPGES levels rose with the increase of HCY in a dose-dependent manner (p<0.01 and p<0.05, respectively). PPAR-gamma activator could significantly inhibit the increase of IL-6 and mPGES induced by 100 micromol/L HCY (p<0.05 and p<0.01, respectively). In conclusion, HCY can increase the expression of IL-6 and mPGES, while PPAR-gamma activator can inhibit the increase of IL-6 and mPGES induced by HCY.
authors.affiliation: Renal Division, Department of Internal Medicine, XiangYa Second Hospital, Center-South University, Hunan, Changsha, China. dongming@mail.csu.edu.cn
authors.forename: Youming
authors.initials: Y
authors.lastname: Peng
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Fuyou
authors.initials: F
authors.lastname: Liu
authors.forename: Haitao
authors.initials: H
authors.lastname: Wang
authors.forename: Yinghong
authors.initials: Y
authors.lastname: Liu
authors.forename: Shaobin
authors.initials: S
authors.lastname: Duan
mesh_terms: D002478:Cells, Cultured; D002839:Chromans / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006710:Homocysteine / Q000494:pharmacology*; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis* / Q000494:pharmacology; D019746:Intramolecular Oxidoreductases / Q000096:biosynthesis*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008861:Microsomes / Q000201:enzymology; D047495:PPAR gamma / Q000187:drug effects / Q000378:metabolism*; D000071876:Prostaglandin-E Synthases; D006435:Renal Dialysis; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D000077288:Troglitazone
chemical_list: D002839:Chromans; D015850:Interleukin-6; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D006710:Homocysteine; D019746:Intramolecular Oxidoreductases; D000071876:Prostaglandin-E Synthases; D000077288:Troglitazone